The EC made its decision based on data from DURATION-NEO-1 clinical trial comparing Bydureon BCise and AZ'[s twice-daily exenatide formulation, Byetta. After 28 weeks of treatment, patients ...
The drugs selected for the report include Mounjaro, Rybelsus, Ozempic, Trulicity, Bydureon, Victoza, Byetta, Invokana, Jardiance and Farxiga. Currently, Medicare Part D covers diabetes drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback